表紙
市場調查報告書

趨化因子受體:機會評估、市場動態、PIPELINE分析 (2019年下半年)

Chemokine Receptors - Opportunity Assessments, Market Dynamics and Pipeline Analytics H2 2019

出版商 GervanoRA Data Services LLP 商品編碼 922699
出版日期 內容資訊 英文 193 Pages
訂單完成後即時交付
價格
趨化因子受體:機會評估、市場動態、PIPELINE分析 (2019年下半年) Chemokine Receptors - Opportunity Assessments, Market Dynamics and Pipeline Analytics H2 2019
出版日期: 2020年01月17日內容資訊: 英文 193 Pages
簡介

目前趨化因子受體基礎的PIPELINE藥物中,共計有92種產品處於臨床階段。其中6種位於第III期、36種位於第II期、12種位於第I期、非臨床試驗階段的產品有34種 (臨床前階段28種、新藥發現階段6種) ,臨床中止的產品也有3種。

本報告分析全球趨化因子受體市場,彙整疾病概要與流行病學趨勢展望、未滿足需求與市場機會、主要資本交易傾向 (併購、合作等)、PIPELINE產品分析與臨床進展情況、目前與未來競爭環境、主要企業SWOT分析、新興企業簡介與市場機會等情報。

第1章 前言

第2章 摘要整理

第3章 趨化因子受體概要

  • 一般考量事項
    • 趨化因子受體類型
  • 趨化因子受體:病理生理學作用
  • 趨化因子受體:範圍

第4章 市場動態:趨化因子受體基礎的治療藥

  • 資本交易(企業合併、收購、合作)
    • 資本交易分析:按交易類型
    • 資本交易分析:按年度頻率
    • 資本交易分析:按疾病領域
  • 專利分析(失效/學名藥化)
  • PIPELINE醫藥品專利分析

第5章 趨化因子受體基礎的治療藥:PIPELINE分析

  • PIPELINE治療藥分析:按開發階段
    • 註冊前階段的PIPELINE治療藥
    • 第III期的PIPELINE治療藥
    • 第II期的PIPELINE治療藥
    • 第I期的PIPELINE治療藥
    • 臨床前階段的PIPELINE治療藥
    • 初期研發階段的PIPELINE治療藥
    • 中斷和終止的PIPELINE治療藥
  • PIPELINE治療藥分析:按地區
    • 未滿足需求與市場機會
  • PIPELINE分析:按投藥路徑
  • PIPELINE分析:按作用機制
  • PIPELINE分析:按治療領域
  • PIPELINE分析:按症狀
  • PIPELINE分析:按標靶
  • PIPELINE分析:按趨化因子受體類型
  • PIPELINE分析:按企業

第6章 臨床階段PIPELINE醫藥品概述與發展里程碑

  • 註冊前階段的開發藥物:概要與臨床里程碑
    • PRO 140 (Leronlimab) - (Cytodyn Inc)
  • 第III期開發藥物概要與開發里程碑
    • Cenicriviroc (CVC) - (Allergan Plc)
    • BKT140/BL-8040 - (BioLineRx/Biokine Therapeutics)
    • Reparixin - (Dompe Farmaceutici SpA)
    • KW-0761 (Mogamulizumab) - (Kyowa Hakko Kirin Co Ltd)
    • Balixafortide (POL6326) - (Polyphor AG)
    • Mavorixafor (X4P-001) - (X4 Pharmaceuticals Inc)
  • 第II期開發藥物:概要與臨床里程碑
    • RIST4721 - (Aristea Therapeutics Inc)
    • CX-01 - (Cantex Pharmaceuticals)
    • CCX140 - (ChemoCentryx)
    • CCX872 - (ChemoCentryx)
    • Vercirnon - (ChemoCentryx)
    • Ladarixin - (Dompe Farmaceutici SpA)
    • E6011 (Quetmolimab) - (Eisai Co., Ltd.)
    • FLX475 - (RAPT Therapeutics - Formerly known as FLX Bio.)
    • LJC242 (Tropifexor (LJN452)/Cenicriviroc (CVC) - (Novartis AG/Allergen Plc)
    • Q-122 - (Que Oncology Inc)
    • SX-682 - (Syntrix Pharmaceuticals)
  • 第I期開發藥物:概要與臨床里程碑
    • CCX507 - (ChemoCentryx)
    • Anti-CXCR1 - (Eli Lilly and Company)
    • RPT193 - (RAPT Therapeutics (舊稱FLX Bio.))
    • GMI-1359 - (GlycoMimetics)
    • MT-0814 - (Mitsubishi Tanabe Pharma Corporation)
    • OB-002H (5P12-RANTES) - (Orion Biotechnology)
    • PF-06835375 - (Pfizer Inc)

第7章 推估核準時程

  • 分析方法
  • 美國國內/國外核準時程 (推估)

第8章 市場機會評估:企業相互比較

  • 外部仰賴
  • PIPELINE產品投資組合
  • 市場參與展望
  • 專利與排他性
  • 銷售動態與合作活動
  • 特殊監管寬放
  • 企業發展

第9章 目前/未來競爭環境評估:企業簡介

  • 既有企業
    • 主要既有企業簡介與SWOT分析
  • 新興企業
    • 主要新興企業簡介

第10章 縮略語

目錄
Product Code: GERPH895

GervanoRA's pipeline analysis and opportunity assessment report "Chemokine Receptors - Opportunity Assessments, Market Dynamics and Pipeline Analytics H2 2019" analyzed and assessed Chemokine Receptors pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Chemokine Receptors based drugs industry.

The report has been divided into segments like Chemokine Receptors Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Chemokine Receptors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Chemokine Receptors based drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Chemokine Receptor Type, Pipeline Analytics by Target, Pipeline Analytics by Therapeutic Area, Pipeline Analytics by Indication and Pipeline Analytics by Companies.

Our comprehensive analysis on the Chemokine Receptors drug pipeline identified 92 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage. Among these, six drug candidates are in the Phase 3 stage of development, thirty-six candidates are in Phase 2 stage, twelve drug candidates are in Phase 1 stage of development and a total of 34 molecules are in non-clinical stage of development. The drug pipeline consists of 28 preclinical drug candidates and six still in their early stages of discovery. One drug candidate is in its registration stage. GervanoRA has also analyzed that there are three drug candidates who have been inactive or were discontinued due to various reasons from further development.

The report has covered a total of 38 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates (Phase 2 and Phase 3 Drug Candidates)
  • Clinical Stage Drug Descriptions along with Development Milestones
  • Opportunity Assessments through Competitive Benchmarking

Evaluate Current and Future Competitive Landscape through Company Profiles:

  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE CHEMOKINE RECEPTORS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. CHEMOKINE RECEPTORS OVERVIEW

  • 3.1 GENERAL CONSIDERATIONS
    • 3.1.1 CHEMOKINE RECEPTOR TYPES
      • 3.1.1.1 CXCR CHEMOKINE RECEPTORS
      • 3.1.1.2 CCR CHEMOKINE RECEPTORS
      • 3.1.1.3 XCR CHEMOKINE RECEPTOR
      • 3.1.1.4 CX3CR CHEMOKINE RECEPTOR
  • 3.2 CHEMOKINE RECEPTORS - ROLE IN PATHOPHISIOLOGY
  • 3.3 CHEMOKINE RECEPTORS - SCOPE

4. MARKET DYNAMICS OF CHEMOKINE RECEPTOR BASED THERAPIES

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 DEALS ANALYTICS BY DEAL TYPE
    • 4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
    • 4.1.3 DEALS ANALYTICS BY DISEASE AREA
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
  • 4.3. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE ANALYTICS OF CHEMOKINE RECEPTOR BASED THERAPIES

  • 5.1. PIPELINE THERAPIES ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION PIPELINE THERAPIES
    • 5.1.2. PHASE 3 PIPELINE THERAPIES
    • 5.1.3. PHASE 2 PIPELINE THERAPIES
    • 5.1.4. PHASE 1 PIPELINE THERAPIES
    • 5.1.5. PRECLINICAL PIPELINE THERAPIES
    • 5.1.6. EARLY R&D PIPELINE THERAPIES
    • 5.1.7. INACTIVE AND DISCONTINUED PIPELINE THERAPIES
  • 5.2. PIPELINE THERAPIES ANALYTICS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYTICS BY MECHANISM OF ACTION
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYTICS BY THERAPEUTIC AREA
  • 5.6. PIPELINE ANALYTICS BY INDICATION
  • 5.7. PIPELINE ANALYTICS BY TARGET
  • 5.8. PIPELINE ANALYTICS BY CHEMOKINE RECEPTOR TYPE
  • 5.9. PIPELINE ANALYTICS BY COMPANY TYPE

6. CLINICAL STAGE PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PRE-REGISTRATION STAGE OF DEVELOPMENT DRUG DESCRIPTION AND DEVELOPMENT MILESTONES
    • PRO 140 (Leronlimab) - (Cytodyn Inc)
  • 6.2. PHASE 3 STAGE OF DEVELOPMENT DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • Cenicriviroc (CVC) - (Allergan Plc)
    • BKT140/BL-8040 - (BioLineRx/Biokine Therapeutics)
    • Reparixin - (Dompe Farmaceutici SpA)
    • KW-0761 (Mogamulizumab) - (Kyowa Hakko Kirin Co Ltd)
    • Balixafortide (POL6326) - (Polyphor AG)
    • Mavorixafor (X4P-001) - (X4 Pharmaceuticals Inc)
  • 6.3. PHASE 2 STAGE OF DEVELOPMENT DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • RIST4721 - (Aristea Therapeutics Inc)
    • CX-01 - (Cantex Pharmaceuticals)
    • CCX140 - (ChemoCentryx)
    • CCX872 - (ChemoCentryx)
    • Vercirnon - (ChemoCentryx)
    • Ladarixin - (Dompe Farmaceutici SpA)
    • E6011 (Quetmolimab) - (Eisai Co., Ltd.)
    • FLX475 - (RAPT Therapeutics - Formerly known as FLX Bio.)
    • LJC242 (Tropifexor (LJN452)/Cenicriviroc (CVC) - (Novartis AG/Allergen Plc)
    • Q-122 - (Que Oncology Inc)
    • SX-682 - (Syntrix Pharmaceuticals)
  • 6.4. PHASE 1 STAGE OF DEVELOPMENT DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • CCX507 - (ChemoCentryx)
    • Anti-CXCR1 - (Eli Lilly and Company)
    • RPT193 - (RAPT Therapeutics - Formerly known as FLX Bio.)
    • GMI-1359 - (GlycoMimetics)
    • MT-0814 - (Mitsubishi Tanabe Pharma Corporation)
    • OB-002H (5P12-RANTES) - (Orion Biotechnology)
    • PF-06835375 - (Pfizer Inc)

7. ESTIMATED APPROVAL TIMELINES

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

8. OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

9. ASSESSMENT OF CURRENT AND FUTURE COMPETITIVE LANDSCAPE THROUGH COMPANY PROFILES

  • 9.1. ESTABLISHED COMPANIES
    • 9.1.1. KEY ESTABLISHED COMPANY PROFILES AND SWOT ANALYSIS
      • 9.1.1.1. ALLERGAN PLC
      • 9.1.1.2. ELI LILLY AND COMPANY
      • 9.1.1.3. ASTRAZENECA PLC
      • 9.1.1.4. PFIZER PHARMACEUTICALS
      • 9.1.1.5. NOVARTIS AG
  • 9.2. EMERGING COMPANIES
    • 9.2.1. KEY EMERGING COMPANY PROFILES
      • 9.2.1.1. ARISTEA THERAPEUTICS INC
      • 9.2.1.2. BIOLINERX LTD
      • 9.2.1.3. KYMAB LTD
      • 9.2.1.4. CHEMOCENTRYX INC
      • 9.2.1.5. POLYPHOR LTD
      • 9.2.1.6. SYNTRIX PHARMACEUTICALS
      • 9.2.1.7. QUE ONCOLOGY INC
      • 9.2.1.8. MAINLINE BIOSCIENCES LLC
      • 9.2.1.9. AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC
      • 9.2.1.10. X4 PHARMACEUTICALS INC
      • 9.2.1.11. CANTEX PHARMACEUTICALS INC
      • 9.2.1.12. GLYCOMIMETICS INC
      • 9.2.1.13. JUVENTAS THERAPEUTICS INC
      • 9.2.1.14. CYTODYN INC
      • 9.2.1.15. RAPT THERAPEUTICS INC

10. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: TOP 10 DEALS INVOLVING CHEMOKINE RECEPTORS RANKED BY DEAL AMOUNT IN M
  • TABLE 03: CHEMOKINE RECEPTORS COLLABORATION DEALS
  • TABLE 04: CHEMOKINE RECEPTORS FINANCING DEALS
  • TABLE 05: CHEMOKINE RECEPTORS LICENSING DEALS
  • TABLE 06: PATENT PORTFOLIO OF PRO 140 (LERONLIMAB) AS OF JUNE 28, 2019
  • TABLE 07: PHASE 3 CHEMOKINE RECEPTOR MOLECULES
  • TABLE 08: PHASE 2 CHEMOKINE RECEPTOR MOLECULES
  • TABLE 09: PHASE 1 CHEMOKINE RECEPTOR MOLECULES
  • TABLE 10: PRECLINICAL CHEMOKINE RECEPTOR MOLECULES
  • TABLE 11: EARLY R&D CHEMOKINE RECEPTOR BASED PIPELINE MOLECULES
  • TABLE 12: INACTIVE AND DISCONTINUED CHEMOKINE RECEPTOR BASE PIPELINE MOLECULES
  • TABLE 13: ADVANCED STAGE CHEMOKINE RECEPTOR MOLECULES AND THEIR APPROVAL REGIONS
  • TABLE 14: ORAL CHEMOKINE RECEPTOR MOLECULES OF CHEMOCENTRYX
  • TABLE 15: LIST OF COMPANIES DEVELOPING PIPELINE MOLECULES FOR ONCOLOGY THERAPEUTIC AREA
  • TABLE 16: LIST OF COMPANIES DEVELOPING PIPELINE MOLECULES FOR ONCOLOGY INDICATIONS
  • TABLE 17: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY TARGET
  • TABLE 18: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY RECEPTOR TYPE
  • TABLE 19: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY COMPANY TYPE
  • TABLE 20: ESTIMATED APPROVAL TIMELINES OF PRE-REGISTRATION AND PHASE 3 MOLECULES (US & EX-US)
  • TABLE 21: ESTIMATED APPROVAL TIMELINES OF PROMISING PHASE 2 MOLECULES (US & EX-US)
  • TABLE 22: TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 23: MAJOR PRODUCTS OF ALLERGAN WITH SALES IN FIRST NINE MONTHS FOR 2019 WITH RESPECT TO THE U.S GENERALIZED MEDICINE SEGMENT
  • TABLE 24: MAJOR PRODUCTS OF ALLERGAN WITH SALES IN FIRST NINE MONTHS FOR 2019 WITH RESPECT TO THE U.S SPECIALIZED TREATMENTS SEGMENT
  • TABLE 25: UNDER DEVELOPMENT PRODUCTS OF ALLERGAN WITH RESPECT TO MEDICAL AESTHETICS TREATMENTS
  • TABLE 26: UNDER DEVELOPMENT PRODUCTS OF ALLERGAN WITH RESPECT TO EYE CARE TREATMENTS
  • TABLE 27: UNDER DEVELOPMENT PRODUCTS OF ALLERGAN WITH RESPECT TO CENTRAL NERVOUS SYSTEM TREATMENTS
  • TABLE 28: UNDER DEVELOPMENT PRODUCTS OF ALLERGAN WITH RESPECT TO GASTROENTEROLOGY
  • TABLE 29: RESEARCH AND DEVELOPMENT ACTIVITIES OF ALLERGAN
  • TABLE 30: RECENT DEVELOPMENTS OF ALLERGAN
  • TABLE 31: ELI LILLY'S TOP PRODUCTS WITH RESPECT TO SALES IN THE FIRST NINE MONTHS OF 2019
  • TABLE 32: ELI LILLY'S COMPOUNDS UNDER DEVELOPMENT WITH RESPECT TO DIABETES
  • TABLE 33: ELI LILLY'S COMPOUNDS UNDER DEVELOPMENT WITH RESPECT TO IMMUNOLOGY
  • TABLE 34: ELI LILLY'S COMPOUNDS UNDER DEVELOPMENT WITH RESPECT TO NEURODEGENERATION
  • TABLE 35: ELI LILLY'S COMPOUNDS UNDER DEVELOPMENT WITH RESPECT TO ONCOLOGY
  • TABLE 36: ELI LILLY'S COMPOUNDS UNDER DEVELOPMENT WITH RESPECT TO PAIN
  • TABLE 37: RESEARCH AND DEVELOPMENT ACTIVITIES OF ELI LILLY
  • TABLE 38: RECENT DEVELOPMENTS OF ELI LILLY
  • TABLE 39: TOP 10 PRODUCTS OF ASTRAZENECA WITH SALES IN FIRST NINE MONTHS FOR 2019 WITH RESPECT TO SALES
  • TABLE 40: PHASE 3 PROGRAMS UNDER ONCOLOGY THERAPY AREA
  • TABLE 41: PHASE 3 PROGRAMS UNDER CARDIOVASCULAR, RENAL AND METABOLISM THERAPY AREA
  • TABLE 42: PHASE 3 PROGRAMS UNDER RESPIRATORY THERAPY AREA
  • TABLE 43: PHASE 3 PROGRAMS UNDER OTHER THERAPY AREAS
  • TABLE 44: RESEARCH AND DEVELOPMENT ACTIVITIES OF ASTRAZENECA
  • TABLE 45: RECENT DEVELOPMENTS OF ASTRAZENECA
  • TABLE 46: PFIZER TOP 5 PRODUCTS UNDER MAJOR PRODUCTS IN BIOPHARMA SEGEMENT
  • TABLE 47: PFIZER TOP 5 PRODUCTS UNDER MAJOR PRODUCTS IN UPJOHN SEGMENT
  • TABLE 48: CLINICAL PROGRAMS UNDER INFLAMMATION AND IMMUNOLOGY AREA
  • TABLE 49: CLINICAL PROGRAMS UNDER INTERNAL MEDICINES
  • TABLE 50: CLINICAL PROGRAMS UNDER ONCOLOGY THERAPY AREA
  • TABLE 51: CLINICAL PROGRAMS UNDER RARE DISEASES
  • TABLE 52: CLINICAL PROGRAMS UNDER VACCINES
  • TABLE 53: RESEARCH AND DEVELOPMENT ACTIVITIES OF PFIZER
  • TABLE 54: RECENT DEVELOPMENTS MADE BY PFIZER
  • TABLE 55: NOVARTIS'S SALES IN MILLION $ OF TOP 10 PRODUCTS IN 9 MONTHS IN 2019
  • TABLE 56: NOVARTIS'S IN REGISTRATION MOLECULES
  • TABLE 57: NOVARTIS'S PHASE 3 MOLECULES
  • TABLE 58: NOVARTIS'S SALES IN MILLION $ OF TOP 10 PRODUCTS IN 9 MONTHS IN 2019
  • TABLE 59: NOVARTIS'S IN REGISTRATION MOLECULES
  • TABLE 60: NOVARTIS'S PHASE 3 MOLECULES
  • TABLE 61: NOVARTIS'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 62: NOVARTIS'S RECENT DEVELOPMENTS
  • TABLE 63: NOVARTIS'S ANTICIPATED MILESTONES
  • TABLE 64: ARISTEA THERAPEUTICS PIPELINE ASSET
  • TABLE 65: R&D ACTIVITIES AND RECENT DEVELOPMENTS OF ARISTEA THERAPEUTICS
  • TABLE 67: BIOLINERX PIPELINE ASSETS
  • TABLE 68: ANTICIPATED MILESTONES OF BIOLINERX
  • TABLE 69: RESEARCH AND DEVELOPMENT ACTIVITIES OF BIOLINERX
  • TABLE 70: PRESENTATIONS AND CONFERENCES OF BIOLINERX
  • TABLE 71: COLLABORATIONS OF BIOLINERX
  • TABLE 72: KYMAB PIPELINE ASSETS
  • TABLE 73: ANTICIPATED MILESTONES OF KYMAB
  • TABLE 74: R&D ACTIVITIES AND RECENT DEVELOPMENTS OF KYMAB
  • TABLE 75: PRESENTATIONS AND CONFERENCES OF KYMAB
  • TABLE 76: CHEMOCENTRYX PIPELINE ASSETS
  • TABLE 77: ANTICIPATED NEAR FUTURE MILESTONES OF CHEMOCENTRYX
  • TABLE 78: RESEARCH AND DEVELOPMENT ACTIVITIES OF CHEMOCENTRYX
  • TABLE 79: RECENT DEVELOPMENTS OF CHEMOCENTRYX
  • TABLE 80: PRESENTATIONS AND CONFERENCES OF CHEMOCENTRYX
  • TABLE 81: POLYPHOR PIPELINE ASSETS
  • TABLE 82: ANTICIPATED NEAR FUTURE MILESTONES OF POLYPHOR
  • TABLE 83: RESEARCH AND DEVELOPMENT ACTIVITIES OF POLYPHOR
  • TABLE 84: RECENT DEVELOPMENTS OF POLYPHOR
  • TABLE 85: PRESENTATIONS AND CONFERENCES OF POLYPHOR
  • TABLE 86: SYNTRIX PIPELINE ASSETS
  • TABLE 87: ANTICIPATED NEAR FUTURE MILESTONES OF SYNTRIX
  • TABLE 88: PATENTS GRANTED TO SYNTRIX
  • TABLE 89: RESEARCH AND DEVELOPMENT ACTIVITIES OF SYNTRIX
  • TABLE 90: RECENT DEVELOPMENTS OF SYNTRIX
  • TABLE 91: PUBLICATIONS OF SYNTRIX
  • TABLE 92: QUE ONCOLOGY PIPELINE ASSET
  • TABLE 94: MAINLINE BIOSCIENCES PIPELINE ASSETS
  • TABLE 95: RESEARCH AND DEVELOPMENT ACTIVITIES OF MAINLINE BIOSCIENCES
  • TABLE 96: RECENT DEVELOPMENTS OF MAINLINE BIOSCIENCES
  • TABLE 97: AMERICAN GENE TECHNOLOGIES PIPELINE ASSETS
  • TABLE 98: PATENTS OF AMERICAN GENE TECHNOLOGIES
  • TABLE 99: RESEARCH AND DEVELOPMENT ACTIVITIES OF AMERICAN GENE TECHNOLOGIES
  • TABLE 100: RECENT DEVELOPMENTS OF AMERICAN GENE TECHNOLOGIES
  • TABLE 101: PUBLICATIONS OF AMERICAN GENE TECHNOLOGIES
  • TABLE 102: X4 PIPELINE ASSETS
  • TABLE 103: ANTICIPATED NEAR FUTURE MILESTONES OF X4
  • TABLE 104: RESEARCH AND DEVELOPMENT ACTIVITIES OF X4
  • TABLE 105: RESEARCH AND DEVELOPMENT ACTIVITIES OF X4
  • TABLE 106: PRESENTATIONS AND CONFERENCES OF X4
  • TABLE 107: CANTEX PIPELINE ASSETS
  • TABLE 108: ANTICIPATED NEAR FUTURE MILESTONES OF CANTEX
  • TABLE 109: RESEARCH AND DEVELOPMENT ACTIVITIES OF CANTEX
  • TABLE 110: RECENT DEVELOPMENTS OF CANTEX
  • TABLE 111: GLYCOMIMETICS' PIPELINE ASSETS
  • TABLE 112: RESEARCH AND DEVELOPMENT ACTIVITIES OF GLYCOMIMETICS
  • TABLE 113: RECENT DEVELOPMENTS OF GLYCOMIMETICS
  • TABLE 114: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF JUVENTAS
  • TABLE 115: RECENT DEVELOPMENTS AND RECENT DEVELOPMENTS OF JUVENTAS
  • TABLE 116: PUBLICATIONS OF JUVENTAS
  • TABLE 117: CYTODYN PIPELINE ASSETS
  • TABLE 118: ANTICIPATED NEAR FUTURE MILESTONES OF CYTODYN
  • TABLE 119: PATENTS OF CYTODYN
  • TABLE 120: RESEARCH AND DEVELOPMENT ACTIVITIES OF CYTODYN
  • TABLE 121: RECENT DEVELOPMENTS OF CYTODYN
  • TABLE 122: RAPT THERAPEUTICS PIPELINE ASSETS
  • TABLE 123: ANTICIPATED NEAR FUTURE MILESTONES OF RAPT THERAPEUTICS
  • TABLE 124: RESEARCH AND DEVELOPMENT ACTIVITIES OF RAPT THERAPEUTICS
  • TABLE 125: RECENT DEVELOPMENTS OF RAPT THERAPEUTICS
  • TABLE 126: CONFERENCES OF RAPT THERAPEUTICS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN THE COMPETITIVE SPACE
  • FIGURE 02: TYPICAL REPESENTATION OF CHEMOKINE RECEPTOR STRUCTURE
  • FIGURE 03: CXCR CHEMOKINE RECEPTOR
  • FIGURE 04: CCR CHEMOKINE RECEPTOR
  • FIGURE 05: XCR CHEMOKINE RECEPTOR
  • FIGURE 06: CX3CR CHEMOKINE RECEPTOR
  • FIGURE 07: ROLE OF CHEMOKINE AND CHEMOKINE RECEPTORS
  • FIGURE 08: CHEMOKINE RECEPTORS DEALS BY DEAL TYPE
  • FIGURE 09: CHEMOKINE RECEPTOR DEALS BY ANNUAL FREQUENCY
  • FIGURE 10: CHEMOKINE RECEPTOR DEALS BY DISEASE AREA
  • FIGURE 11: CHEMOKINE RECEPTOR PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • FIGURE 12: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 13: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY ROA
  • FIGURE 14: CHEMOKINE RECEPTOR BASED PIPELINE ANALYSIS BY THERAPEUTIC AREA
  • FIGURE 15: CHEMOKINE RECEPTOR PIPELINE ANALYSIS BY COMPANY TYPE
  • FIGURE 16: RANKIG TOP 5 COMPANIES BASED ON RESEARCH AND DEVELOPMENT EXPENSES IN $M
  • FIGURE 17: COMPETITIVE BENCHMEARKING - PIPELINE PORTFOLIO WITH NUMBER OF MOLECULES
  • FIGURE 18: EXPECTED MARKET ENTRIES IN THE U.S WITH RESPECT TO CHEMOKINE RECEPTOR BASED COMPOUNDS
  • FIGURE 19: TIME LINE OF PATENT EXPIRIES WITH RESPECTIVE TO CHEMOKINE RECEPTOR BASED COMPOUNDS
  • FIGURE 20: RANKING TOP 6 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 21: RESEARCH AND DEVELOPMENT EXPENSES AS WELL AS NET SALES FOR YEARS 2016, 2017 AND 2018 MADE BY ALLERGAN
  • FIGURE 22: PRODUCT SALES AND RESEARCH AND DEVELOPMENT EXPENSES FOR THE FIRST NINE MONTHS OF 2018 AND 2019
  • FIGURE 23: RESEARCH AND DEVELOPMENT EXPENSES AS WELL AS NET PRODUCT REVENUES FOR YEARS 2016, 2017 AND 2018 MADE BY ELI LILLY
  • FIGURE 24: RESEARCH AND DEVELOPMENT EXPENSES AS WELL AS NET PRODUCT REVENUES FOR YEARS 2016, 2017 AND 2018 MADE BY ELI LILLY
  • FIGURE 25: RESEARCH AND DEVELOPMENT EXPENSES AS WELL AS NET SALES FOR YEARS 2016, 2017 AND 2018 MADE BY ASTRAZENECA
  • FIGURE 26: ASTRAZENECA'S SALES FOR THE THIRD QUARTER AS WELL AS THE FIRST NINE MONTHS OF 2019
  • FIGURE 27: FINANCIAL INFORMATION OF PFIZER FOR 2016, 2017 AND 2018
  • FIGURE 28: REVENUE BREAKDOWN BETWEEN PFIZER'S SEGMENTS FOR THE FIRST NINE MONTHS ENDED IN 2019
  • FIGURE 29: NOVARTIS'S REVENUES EARNED IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 30: NOVARTIS'S BREAKDOWN OF REVENUES EARNED IN THE YEAR END OF 2018
  • FIGURE 31: RESEARCH AND DEVELOPMENT EXPENSES IN THOUSAND $ FOR YEAR ENDED DECEMBER 31(2016, 2017 AND 2018)
  • FIGURE 32: RESEARCH AND DEVELOPMENT EXPENSES OF CHEMOCENTRYX IN THOUSANDS FOR THE THREE MONTHS ENDED SEPTEMBER 30(2018 AND 2019)
  • FIGURE 33: GLYCOMIMETICS' RESEARCH AND DEVELOPMENT EXPENSES FOR THE YEARS OF 2016, 2017 AND 2018
  • FIGURE 34: RESEARCH AND DEVELOPMENT EXPENSES OF CYTODYN FOR THE YEARS ENDED MAY 31 (2018 AND 2019)
  • FIGURE 35: RESEARCH AND DEVELOPMENT EXPENSES OF RAPT THERAPEUTICS IN THOUSANDS FOR THE THREE MONTHS AND FOR THE NINE MONTHS ENDED SEPTEMBER 30 (2018 AND 2019)